TY - JOUR
T1 - Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
AU - Yamada, Eiko
AU - Takagi, Ritsuo
AU - Tanabe, Yoshinari
AU - Fujiwara, Hiroshi
AU - Hasegawa, Naoki
AU - Kato, Shingo
N1 - Publisher Copyright:
© 2017 Dustri-Verlag Dr. K. Feistle.
PY - 2017
Y1 - 2017
N2 - Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.
AB - Objective: We studied the relationships between plasma and saliva concentrations of antiretroviral drugs to explore whether saliva can be used for therapeutic drug monitoring (TDM). Methods: Abacavir (ABC), tenofovir (TFV), darunavir (DRV), and raltegravir (RAL) in plasma and saliva from 30 HIV-1-infected patients were quantified using liquid chromatography-tandem mass spectrometry. Results: Mean salivato- plasma concentration ratios were 0.623 (ABC), 0.024 (TFV), 0.065 (DRV), and 0.0135 (RAL), which agree with the plasma protein binding rates except TFV. Significant correlations were evident between saliva and plasma concentrations of ABC, DRV, and RAL. Conclusions: This study suggests that plasma concentrations of ABC, DRV, and RAL can be estimated from their saliva concentrations and that the saliva concentration of some antiretroviral drugs reflects the unbound drug concentration in plasma.
KW - Antiretroviral therapy
KW - HIV-1 infection
KW - Pre-exposure prophylaxis
KW - Saliva
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=85021275147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021275147&partnerID=8YFLogxK
U2 - 10.5414/CP202789
DO - 10.5414/CP202789
M3 - Article
C2 - 28427498
AN - SCOPUS:85021275147
SN - 0946-1965
VL - 55
SP - 567
EP - 570
JO - International Journal of Clinical Pharmacology and Therapeutics
JF - International Journal of Clinical Pharmacology and Therapeutics
IS - 7
ER -
